GPCM
MDGL icon

Granite Point Capital Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Granite Point Capital Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-4,418
Closed -$40K – 106
2016
Q2 		$40K Buy
+4,418
New +$53K 0.02% 82

Other funds holding MDGL

CC
Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Granite Point Capital Management's MDGL Position: Q3 2016 in Review

Granite Point Capital Management sold out of Madrigal Pharmaceuticals (MDGL) in Q3 2016, closing a stake of 4,418 shares — an estimated $40K sold.

Granite Point Capital Management first reported a position in MDGL in Q2 2016 and held it in 1 quarter. The position peaked at $40K in Q2 2016. 31 funds tracked by Wall St. Rank hold MDGL as of Q3 2016.

  • Granite Point Capital Management reported no remaining Madrigal Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Granite Point Capital Management sold 4,418 Madrigal Pharmaceuticals shares in Q3 2016, an estimated $40K.
  • Granite Point Capital Management first reported a position in Madrigal Pharmaceuticals in Q2 2016 and held it in 1 quarter.
  • Granite Point Capital Management's Madrigal Pharmaceuticals position peaked at $40K in Q2 2016.
  • 31 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2016.

Based on Granite Point Capital Management's 13F filing for Q3 2016, filed 9 Nov 2016.